Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02207881
Other study ID # YSP-RMN3001-01
Secondary ID
Status Completed
Phase Phase 2
First received July 31, 2014
Last updated April 13, 2016
Start date July 2014
Est. completion date December 2015

Study information

Verified date July 2014
Source Yung Shin Pharm. Ind. Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority Taiwan : Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Recurrent herpes labialis are usually a minor malady of limited duration, although they are often painful and are uniformly discomforting for patients. Oral antivirals represent an advance in the treatment of recurrent herpes labialis, but the clinical implications are modest. Randomized, controlled clinical trials have shown that oral antivirals decrease the duration of lesion episodes and pain by approximately one day. In recurrent HSV infections including herpes labialis, many instances of viral re-activation occur without symptoms, and can only be identified by detection of virus on the lips of infected individuals. In these cases, the virus is cleared from the local site without the development of a classical ulcerative herpes lesion. In the other cases, the triggered specific immune response rapidly stops viral replication in the skin and also causes the development of the herpes lesion prodrome and a considerable part of the symptoms associated with a classical ulcerative herpes lesion. One could therefore predict that treatment with an antiviral drug alone would help the immune system in shortening the virus replication, but may not substantially reduce the disfiguring symptoms caused by the immune reaction. In dermatology, the principle of using an anti-inflammatory drug improve clinical outcomes by reducing inflammation-related symptoms associated with the infection has been well established. We have found that a topical formulation of VDO is useful for alleviating pain and inflammation associated with infection caused by herpes virus.


Description:

In the treatment of oral herpes labialis, it is desirable to have local absorption of the drug to provide pain relief directly at the lesion sites while minimizing overall exposure.

The present study is designed to elucidate the effects of VDO ( on recurrent herpes simplex labialis.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

- Male or female in the age group 20 to 75 years old.

- History of recurrent herpes labialis with at least one recurrence occurred during the past twenty-four months.

- Onset of prodrome, erythema or vesicle within 72 hours of initiation of treatment with the study drug.

- Subjects with previous herpes simplex labialis episodes must be healed for at least 14 days before the baseline.

- Must be willing and able to participate and to provide written informed consent.

- Female subjects of childbearing potential must have a negative pregnancy test at screening and agree to use a proper contraceptive method during the study.

Exclusion Criteria:

- Women during pregnancy, lactation or breastfeeding.

- Subjects using topical steroids on or near the face or systemic (oral, intravenous) steroids within 7 days prior to study drug administration; use of inhaled or nasal spray steroids does not exclude a subject from the study.

- Subjects have used anti-viral agents or NSAID in the preceding 7 days.

- Subjects are unwilling to stop for using topical medical, OTC, cosmetic or facial skin care products in or around the oral area during the study period.

- Subjects with immunodeficiency disorders such as human immunodeficiency virus (HIV) infection or receiving cancer chemotherapy.

- Subjects who have a history of hypersensitivity to diclofenac, lidocaine or propylene glycol.

- Subjects who have a known hypersensitivity to local anesthetics of the amide type, diclofenac, aspirin, or other NSAIDs.

- Subjects who are taking antiarrhythmics drug during screening visit;

- Subjects who have a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.

- Subjects who use during the perioperative period in the setting of coronary artery bypass graft (CABG) surgery within 6 months before the study drug using.

- Subjects have history of substance abuse or psychiatric illness that would preclude compliance with the protocol.

- Subjects who have serious, unstable, or clinically significant medical or psychological conditions, which, in the opinion of the investigator(s), would compromise the subject's participation in the study (including clinically significant dehydration or unstable vital signs).

- Subjects taking or having taken any other experimental drugs, drugs not approved in Taiwan, or participating in or having participated in other clinical studies in the 30 days prior to this clinical trial.

- Subjects who are considered unreliable as to medication compliance or adherence to scheduled appointments, or inappropriate for inclusion determined by the investigators.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
VDO gel
VDO gel
placebo
matching placebo gel

Locations

Country Name City State
Taiwan Changhua Christian Hospital Changhua

Sponsors (2)

Lead Sponsor Collaborator
Yung Shin Pharm. Ind. Co., Ltd. Changhua Christian Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse event Incidences of adverse event at the end of treatment (up to 10 days) Yes
Secondary the duration and severity of pain Pain intensity will be measured at baseline and in the Subject's DRC on a daily basis while receiving study drug until end of study. Pain and itching assessments will be using a Visual Analogue Scale (VAS) ranging 0 (no pain/itching) to 10 (the worst pain/itching imaginable).
The subject will be asked the following question exactly as follows:?On a scale 1 to 10 where 0 means on pain/itching, and 10 means the worst possible pain/itching, rate the worst pain/itching that you have since last assessment?
At the end of treatment (up to 10 days) No
See also
  Status Clinical Trial Phase
Completed NCT02483182 - Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores Phase 2
Completed NCT00297011 - Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis Phase 2
Completed NCT03310294 - Immune Evidence to the Consumption of Lactobacillus GG and FOS Consumption in Patients With Herpes Labialis N/A
Terminated NCT04539483 - Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection Phase 2
Completed NCT02265913 - Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis Phase 3
Completed NCT01971385 - Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis Phase 1
Active, not recruiting NCT01695187 - NB-001 Treatment of Recurrent Herpes Labialis Phase 3
Completed NCT00375570 - Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents Phase 3
Completed NCT02871492 - Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes Phase 2
Completed NCT01484067 - Study of a Cold Sore Patch for the Treatment of Herpes Labialis N/A
Completed NCT00769314 - Phase 3 Clinical Study for the Treatment of Cold Sore Phase 3
Completed NCT00878072 - Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis Phase 2/Phase 3
Completed NCT01574612 - Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old Phase 3
Completed NCT03661541 - Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1) Phase 1
Recruiting NCT01306084 - Viral Infections in Healthy and Immunocompromised Hosts
Terminated NCT03521479 - A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis Phase 2
Terminated NCT00913692 - A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis Phase 2
Completed NCT01653509 - An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode Phase 1
Completed NCT00361881 - Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis Phase 3
Recruiting NCT02582086 - Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis N/A